| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
The present study demonstrated that josamycin, a macrolide antibiotic, inhibited the development of Th1 and Th2 cells mediated by Langerhans cells and topical treatment with josamycin significantly suppressed the increase in the skin severity score in NC/Nga mice. Furthermore, Staphylococcus aureus strains isolated from skin lesions of patients with atopic dermatitis were highly susceptible to josamycin. Therefore, topical application of josamycin to atopic dermatitis lesions colonized by S. aureus would be beneficial for control of dermatitis and preferable to steroids.
|
